Oral Thin Films Global Market Report 2026

An oral thin film (OTF) is an extremely thin polymeric film designed for application in the mouth. The primary purpose of oral thin films is to deliver therapeutic substances into the oral cavity or the gastrointestinal tract, facilitating absorption and direct transportation into the circulatory system.

The main types of oral thin films include sublingual films and fast-dissolving dental/buccal films. Sublingual films rapidly dissolve under the tongue, facilitating quick absorption through the tissue and direct entry into the bloodstream. These films are often used in the treatment of conditions such as opioid misuse disorder recovery. Additionally, oral thin films are employed in the treatment of various conditions like schizophrenia, migraine, opioid dependence, nausea, and vomiting. These films are typically distributed through hospital pharmacies, retail pharmacies, and other relevant distribution channels.

Tariffs are influencing the oral thin films market by increasing costs of imported pharmaceutical polymers, active pharmaceutical ingredients, packaging materials, and precision coating equipment. Manufacturing hubs in North America and Europe are most affected due to reliance on imported raw materials, while Asia-Pacific faces pricing pressure in export-oriented production. These tariffs are increasing production costs and affecting pricing strategies. However, they are also encouraging local sourcing of excipients, domestic manufacturing expansion, and innovation in cost-efficient oral film formulations.

The oral thin films market research report is one of a series of new reports from The Business Research Company that provides oral thin films market statistics, including oral thin films industry global market size, regional shares, competitors with a oral thin films market share, detailed oral thin films market segments, market trends and opportunities, and any further data you may need to thrive in the oral thin films industry. This oral thin films market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral thin films market size has grown rapidly in recent years. It will grow from $4.99 billion in 2025 to $5.72 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to growing preference for non-invasive drug delivery, expansion of psychiatric and neurological treatments, rising demand for fast-acting therapies, increasing acceptance of otc drug formats, improvements in pharmaceutical film manufacturing.

The oral thin films market size is expected to see rapid growth in the next few years. It will grow to $9.82 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to increasing adoption of personalized medicine delivery, rising investments in novel polymer formulations, expansion of otc oral therapeutics, growing focus on pediatric and geriatric care, increasing demand for rapid onset therapies. Major trends in the forecast period include increasing adoption of rapid-acting drug delivery films, rising demand for patient-friendly dosage forms, growing use of polymer-based film technologies, expansion of otc oral film products, enhanced focus on improved bioavailability.

The growing demand for thin film drug delivery systems is fueling the expansion of the oral thin film market. Thin films have emerged as a promising alternative to traditional dosage forms due to their convenience, self-administration, and fast-dissolving nature, making them a versatile drug delivery platform. These films are taken orally and do not require water for ingestion, allowing for efficient drug absorption. Oral thin films (OTFs) are particularly patient-friendly due to their rapid dissolution rate. As a result, the demand for thin film drug delivery systems is rising, driving increased interest in oral thin films. In the United States, cardiovascular disease affects over half the population. For example, in January 2023, a report from The American Cancer Society, a US-based nonprofit organization, noted that at least 42% of newly diagnosed cancers in the US, excluding non-melanoma skin cancer, accounted for approximately 820,000 cases in 2023, with a projected 840,000 cases in 2024. This underscores the growing need for advanced drug delivery systems to ensure effective treatment. Consequently, the increasing demand for thin film drug delivery systems is boosting the growth of the oral thin film market.

Leading companies in the oral thin films market are focusing on innovative products like Rizaport to boost their revenue. Rizaport is a branded oral thin film that contains rizatriptan benzoate, a 5-HT1 receptor agonist and the active ingredient in Merck & Co.'s Maxalt. For example, in February 2024, CD Formulation, a US-based drug formulation company, introduced its oral thin film technology. This product is designed for easy administration, particularly for patients who have difficulty swallowing, and ensures rapid absorption by dissolving in the oral cavity, bypassing the digestive system for quicker onset of action. This cutting-edge drug delivery system enhances bioavailability, provides accurate dosing for individualized treatment, and improves both convenience and medication adherence, especially in urgent situations.

In April 2023, DifGen Pharmaceuticals LLC, a United States-based healthcare technology company, completed the acquisition of Aveva Drug Delivery Services Inc. for an undisclosed consideration. Through this transaction, DifGen sought to broaden its research and development and manufacturing capabilities in advanced drug delivery dosage forms, establish a manufacturing presence within the United States, strengthen supply chain resilience, and enhance its ability to provide affordable, high-quality, life-saving medicines. Aveva Drug Delivery Services Inc. is a United States-based manufacturing company focused on the development and production of transdermal delivery systems and oral dissolvable film technologies.

Major companies operating in the oral thin films market are ZIM Laboratories Limited, Cure Pharmaceutical Holding Corp., IntelGenx Corp., Aquestive Therapeutics Inc., BioDelivery Sciences International Inc., Indivior PLC, LTS Lohmann Therapie-Systeme AG, Tesa Labtec GmbH, APR Applied Pharma Research SA, NAL Pharma, Panacea Biotec Ltd., Shilpa Therapeutics Pvt. Ltd., LIVKON Pharmaceuticals Pvt. Ltd., Kyu Kyu Pharmaceutical Co. Ltd., Seoul Pharma Co. Ltd., Adare Pharmaceuticals Inc., Sumitomo Dainippon Pharma Co. Ltd., Sunovion Pharmaceuticals Inc., MonoSol Rx LLC, C.L. Pharm Co. Ltd.

North America was the largest region in the oral thin film market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral thin films market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral thin films market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The oral thin films market consists of sales of orally disintegrating and orally dissolving films. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Thin Films Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses oral thin films market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral thin films ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oral thin films market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Sublingual Film; Fast Dissolving Dental/Buccal Film
• 2) By Disease Indication: Schizophrenia; Migraine; Opioid Dependence; Nausea & Vomiting; Other Disease Indications
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Sublingual Film: Drug Delivery Films; Nutritional Supplement Films
• 2) By Fast Dissolving Dental Or Buccal Film: Over-the-Counter (OTC) Products; Prescription Products
• Companies Mentioned: ZIM Laboratories Limited; Cure Pharmaceutical Holding Corp.; IntelGenx Corp.; Aquestive Therapeutics Inc.; BioDelivery Sciences International Inc.; Indivior PLC; LTS Lohmann Therapie-Systeme AG; Tesa Labtec GmbH; APR Applied Pharma Research SA; NAL Pharma; Panacea Biotec Ltd.; Shilpa Therapeutics Pvt. Ltd.; LIVKON Pharmaceuticals Pvt. Ltd.; Kyu Kyu Pharmaceutical Co. Ltd.; Seoul Pharma Co. Ltd.; Adare Pharmaceuticals Inc.; Sumitomo Dainippon Pharma Co. Ltd.; Sunovion Pharmaceuticals Inc.; MonoSol Rx LLC; C.L. Pharm Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.